|
Middle East Fertility Society Journal
Middle East Fertility Society
ISSN: 1110-5690
Vol. 10, Num. 2, 2005, pp. 130-134
|
Middle East Fertility Society Journal, Vol. 10, No. 2, 2005, pp. 130-134
Clomiphene-acetyl cysteine combination as a new
protocol to a friendly IVF cycle
Ahmed
Y Rizk, M.D.*, Mohamed
A Bedaiwy, M.D., Hesham
G. Al- Inany, M.D.
Departments
of Obstetrics and Gynecology, Benha University, Assiut School of Medicine, Assiut,
and
Cairo
University,
Egypt
*Department of Obstet and Gynecol, Benha University, Egypt,
Department of Obstet and Gynecol Assiut School of Medicine, Assiut,
Egypt
Department of Obstet and Gynecol, Cairo University, Egypt
Reprint request: Ahmad Rezk, Benha University, P.O 113, Benha, Egypt, E-mail
: kaainih@link.net; ahmadrezk@yahoo.com
Received
January 17, 2005; revised and accepted May 18, 2005
Code Number: mf05024
ABSTRACT
Objective: N-acetyl-cysteine (NAC) has been shown
to enhance the action of clomiphene citrate in ovulation induction. The
objective of this study was to examine the use of NAC with clomiphene citrate
for ovarian stimulation in assisted conception as a model for "Friendly
IVF"
Design: pilot study
Materials and methods: Twenty infertile patients
undergoing IVF/ICSI cycles were offered NAC, 1,200 mg/day from day 3-7 of the
menstrual
cycle with CC (100 mg /day) starting on day 3-7. hCG (10,000 IU) was given when
leading follicle(s) were ≥ 18mm followed by ICSI.
Main outcome
measure(s): clinical
pregnancy rate was the primary outcome and implantation rate, number of oocytes
retrieved, fertilization rate were secondary outcomes
Result(s): response to CC stimulation with NAC
co-treatment was evident by a number of mature follicles ranging from 2-7 at
the time of hCG administration. Clinical pregnancy was achieved in 4 cycles
(20%).
Conclusion(s): In this preliminary report, a potential
benefit of NAC co-treatment with CC in young women undergoing IVF/ICSI cycles
was demonstrated. This combination provides a cheap, effective way for
ovulation induction in an IVF setting compatible with the concept of friendly
IVF
Keywords: N-acetyl-cysteine; clomiphene citrate,
Friendly IVF, ICSI, pregnancy
Increasing efficiency of
various assisted reproduction techniques has been obtained by using more
aggressive hormone stimulation protocols and improved laboratory techniques for
gamete and embryos. However, this was on the expense of increased costs, high
multiple pregnancy rates, and side effects of stimulation regimens. Controlled
ovarian hyperstimulation in in vitro fertilization (IVF) aimed at increased
oocyte and embryo numbers to compensate for a poor implantation rate per
embryo. Given the fact that implantation are (30% in the majority of
IVF clinics in patients below 40 years of age, it seems necessary to explore
more `friendly IVF' regimens to obtain a reasonable pregnancy rate, ideally
resulting in the delivery of a single, healthy child (1). The ideal IVF
protocol secures a high chance of embryo transfer and accordingly a low
cancellation rate, a high pregnancy rate, a low intervention level, low risk
and few side-effects, low costs and practical convenience both for the patient
and the clinician (2).
Natural cycle meets some
of these criteria, however this was on the expense of a relatively high
cancellation rate (25-75%) and a low clinical pregnancy rate per started cycle
(range 0-23%), but higher per embryo transfer (range 0-30%) (3-5). The main
problems with natural cycle IVF are spontaneous LH surge and ovulation, almost
always single oocyte retrieved, low fertilization rates, high cancellation rate
and low pregnancy and implantation rates. The latter problems associated with
natural cycles were partially overcome by a mild stimulation yielding better
chances of collecting more than one oocyte. Clomiphene citrate has been used
(6).
Recently we have shown
that N-acetyl cysteine (NAC) is a potent adjuvant to CC in CC resistant PCOS
patients (7). NAC as an adjuvant to clomiphene citrate was more effective than
placebo in those patients. Combination of CC and NAC significantly increased
both ovulation rate and pregnancy rate in women with CC resistant PCOS (49.3%
vs 1.3 and 21.3% vs 0% respectively). No cases of ovarian hyperstimulation
syndrome were reported in the NAC group (7).
The purpose of the
present study was to evaluate the efficiency of using a combination of CC and
NAC in a cohort of women undergoing IVF / ICSI cycles.
MATERIALS AND METHODS
This pilot study was
performed between September 2003 and July 2004. Twenty couples with previous
IVF failure were invited to participate in the present study with the following
inclusion criteria: age <39 years, infertility unexplained, tubal or due to
severe male factor with indication for ICSI, regular menstrual cycles (± 3
days), presence of two ovaries. All patients gave written informed consent
after counseling, and the study was approved by the Ethics Committee. At entry
all patients received a combination of clomiphene citrate 100 mg from cycle day
3-7 and NAC (Sedico, Cairo, ARE), in a dose of 1.2
g/day orally, with timing of oocyte retrieval by human chorionic gonadotrophin
(HCG) injection. All patients received one treatment cycle.
Cycle monitoring
All cycles
were monitored by vaginal ultrasound on cycle day 3, and subsequently on day 9
and day 11 and thereafter as necessary. All cycles were followed until the
dominant follicle was 18 mm and then HCG (Pregnyl; 10000 IU) was given followed
by oocyte retrieval 35-36 h later.
Oocyte retrieval, injection and embryo
culture
Oocyte retrieval was
performed by ultrasound-guided transvaginal aspiration using a single-lumen
needle (CCD, France) with careful flushing of each follicle. Oocytes were
denuded with hyaluronidase (Vitrolife Fertility Systems, Gothenburg, Sweden) and mechanical
pipetting. Mature (metaphase II) oocytes were identified by the presence of the
first polar body. Only those oocytes that had extruded the first polar body
(metaphase II oocytes) were microinjected.
Immediately before
injection, the sperm suspension was added to a 50 µl droplet of polyvinylpyrrolidone
(ICSI Scandinavia, Sweden). Oocytes were microinjected ~5 h after retrieval in
microdroplets of IVF medium covered with lightweight paraffin oil. A single
motile spermatozoon with apparently normal morphology was immobilized by
touching its tail with the injection pipette and aspirated tail-first into the
injection pipette. The sperm was microinjected into the ooplasm at the 3 o'clock position, the polar
body being oriented at the 6 o'clock position.
Fertilization was
assessed 24 h after injection if two pronuclei (2PN) were present and the
second polar body had been extruded, then left in culture for a further 24 h.
Embryos were transferred
48-72 h after oocyte retrieval using Labotect embryo transfer catheter, (Labotect
GmbH, Labor-Technik-Gottingen, Germany). Routinely, a maximum
of four embryos were transferred to the patient. luteal phase support was given
using oral micronised progesterone (utrogestan (two tablets bid) (October
Pharma SAE, Under license of Besins International, S.A. France) .
Pregnancy was determined
by serum HCG measurement on day 14-15 after transfer and clinical pregnancies
were detected by presence of a gestational sac on ultrasound scans performed 6
weeks after embryo transfer. The implantation rate was defined as (the number
of gestational sacs divided by the number of
embryos transferred) x 100.
Table 1. Descriptive statistics for NAC-CC cycles
|
Number of follicles
|
Number of oocytes
|
Number of 2PN
|
Number of embryos
transferred
|
|
|
|
|
|
Mean
|
4.8
|
3.6
|
2.6
|
2.5
|
SD
|
1.6
|
1.2
|
1.2
|
0.9
|
Median
|
5
|
3.5
|
2
|
2
|
Minimum
|
2
|
2
|
1
|
1
|
Maximum
|
7
|
5
|
5
|
4
|
Data were statistically represented in terms of
mean, median, minimum, maximum and standard deviation (S.D.) where appropriate.
RESULTS
Twenty women were
enrolled in this pilot study with mean age of 27.3±1.9 and mean BMI of
28.1±0.8.
The mean number of
follicles >14 mm on the day of HCG injection was 4.8±1.6. Only one cycle was
cancelled due to premature LH surge. The mean number of oocytes retrieved was
3.6±1.2. (Table 1) Four women got pregnant (20%) [all were single ton pregnancy
except one twin). No miscarriage was reported till now.
On estimating the cost
of medications used, the number of NAC sachets used was 6 per day for 5 days
making a total of 30 costing 27 E.P plus an average two fillings of Clomid = 18
EP, thus the total cost of medications in NAC-CC / ICSI cycle = 45 E.P (7$)
which is dramatically different from the average cost of medications in the
long protocol of ICSI cycle (about 2000EP) (~ 450$)
DISCUSSION
The current
study has demonstrated that it is possible to obtain reasonable results using
an IVF protocol with a combination of NAC-CC for ovarian stimulation. The
relatively young age of the population should be borne in mind when considering
the relatively high pregnancy rates in the NAC-CC/ICSI series. The concomitant
administration of NAC did not influence oocyte maturity in terms of metaphase
II oocytes. Ideally, the efficiency of the NAC-CC/ICSI protocol should be
compared with those obtainable from the current `gold standard', the long
down-regulation protocol, in a similar population. Such analyses should be
considered in the future, also in terms of cost-effectiveness and clients'
perceptions.
In the present study,
there was no cycle cancellation. This could be due to small sample size or due
to using selection potentially high responders. One point of importance is that
LH surge should be tested in friendly IVF protocol. Although we did not perform
such monitoring, we got high fertilization rate. Fertilization rate of 80% and
an implantation rate of 14.3% obtained in the present series following NAC-CC
stimulation, are higher than in unstimulated cycles (8). The proportion of
unfertilized oocytes in unstimulated conventional IVF cycles in a recent study
(2) was 53%. However, ICSI seems to be an efficient tool in an unstimulated or
low stimulation protocol as indicated in previous studies (9).
The negative anti-estrogenic
effect of clomiphene citrate on various parts of the human reproductive system
(10) seems to be counteracted by the concomitant administration of NAC. Natural
IVF did not achieve satisfactory results, as the pregnancy rate per cycle is
10% or below (3, 5, 11-16), but others have obtained higher rates, up to 23%.
However the intensive monitoring needed is not compatible with the `friendly
IVF' concept. A 20% pregnancy rate in our series is higher than previous
reports using natural cycle IVF with obviously less monitoring involved.
Recently a consistent
delivery rate of ~22% per started cycle has been observed during the last few
years, accomplished mainly by the long down-regulation protocol and two-embryo
transfers (17). Similar results were obtained with single embryo transfer (18).
Consequently, calling for a mild ovarian stimulation which provides less number
of embryos and a relatively comparable pregnancy is feasible. NAC-CC thus seems
to be not only compatible with the concept of friendly IVF engraved by
Olivennes (1) but with the growing interest in single embryo transfer as well.
In a randomized study
Ingerslev and colleagues proposed that the clinical pregnancy rate per cycle
using CC stimulation could be improved by reducing the rather high cycle
cancellation rate. The frequency of cycle cancellation due to lack of
fertilization could be less if more oocytes were harvested. They proposed
adding FSH, including antagonists into the protocol or closer endocrine
monitoring as alternative means of reducing the risk of cycle cancellation due
to spontaneous ovulation. However, these suggestions would reduce the `friendliness' of the protocol (2).
NAC
treatment has an insulin sensitizing effect and it induced a significant fall
in testosterone levels and in free androgen index values (19, 20). NAC is
commonly used as a safe mucolytic drug, and at higher doses it increases the
cellular levels of reduced glutathione (GSH), an antioxidant, which has been
shown to influence insulin receptor activity. More recently, it has also been
shown to have other diverse biological effects notably; antiapoptotic (21),
antioxidant (22), protection against focal ischemia (23), inhibition of
phospholipid metabolism, preinflammatory cytokine release, and protease
activity (24). NAC may exert the same effects at the ovarian level and these
activities may be central in inducing ovulation.
In
conclusion, the present study suggests that a simple NAC-CC protocol is
compatible with the concept of `friendly IVF', yielding a reasonable pregnancy
rate per cycle started. The results of this study should be substantiated in a
larger cohort of patients.
REFERENCES
-
Olivennes
F, Frydman R. Friendly IVF: the way of the future? Hum Reprod
1998;13(5):1121-4.
-
Ingerslev
HJ, Hojgaard A, Hindkjaer J, Kesmodel U. A randomized study
comparing IVF in the unstimulated cycle with IVF following clomiphene citrate.
Hum Reprod 2001;16(4):696-702.
-
Fahy UM,
Cahill DJ, Wardle PG, Hull MG. In-vitro fertilization in completely natural
cycles. Hum Reprod 1995;10(3):572-5.
-
Seibel
MM, Kearnan M, Kiessling A. Parameters that predict success for natural cycle
in vitro fertilization-embryo transfer. Fertil Steril 1995;63(6):1251-4.
-
Kim
SH, Kim CH, Suh CS, Moon SY, Lee JY, Chang YS. Simultaneous program of
natural-cycle in vitro fertilization and cryopreserved-thawed embryo transfer.
J Assist Reprod Genet 1996;13(9):716-21.
-
Tarlatzis BC, Grimbizis G. Future use
of clomiphene in ovarian stimulation. Will clomiphene persist in the 21st
century? Hum Reprod 1998;13(9):2356-8.
-
Rezk
A, Bedaiwy MA, Al-Inany H. N-Acetyl Cysteine is a novel adjuvant to clomiphene
citrate in clomiphene resistant polycystic ovary syndrome patients. Fertil
Steril 2005; 83(2): 367-70
-
Foulot
H, Ranoux C, Dubuisson JB, Rambaud D, Aubriot FX, Poirot C. In vitro
fertilization without ovarian stimulation: a simplified protocol applied in 80
cycles. Fertil Steril 1989;52(4):617-21
-
Ludwig
M, al-Hasani S, Kupker W, Bauer O, Diedrich K. A new indication for an
intracytoplasmic sperm injection procedure outside the cases of severe male
factor infertility. Eur J Obstet Gynecol Reprod Biol 1997;75(2):207-10.
-
Out HJ, Coelingh Bennink
HJ. Clomiphene citrate or gonadotrophins for induction of ovulation? Hum Reprod
1998;13(9):2358-61.
-
Paulson RJ, Sauer MV,
Francis MM, Macaso TM, Lobo RA. In vitro fertilization in unstimulated
cycles: the University of Southern California experience. Fertil
Steril 1992;57(2):290-3.
-
Lenton EA, Cooke ID,
Hooper M, King H, Kumar A, Monks N, et al. In vitro fertilization in the
natural cycle. Baillieres Clin Obstet Gynaecol 1992;6(2):229-45.
-
Taymor ML, Ranoux CJ,
Gross GL. Natural oocyte retrieval with intravaginal fertilization: a
simplified approach to in vitro fertilization. Obstet Gynecol
1992;80(5):888-91.
-
Claman P, Domingo M,
Garner P, Leader A, Spence JE. Natural cycle in vitro fertilization-embryo
transfer at the University of Ottawa: an inefficient therapy
for tubal infertility. Fertil Steril 1993;60(2):298-302.
-
MacDougall MJ, Tan SL,
Hall V, Balen A, Mason BA, Jacobs HS. Comparison of natural with clomiphene
citrate-stimulated cycles in in vitro fertilization: a prospective, randomized
trial. Fertil Steril 1994;61(6):1052-7.
-
Daya S, Gunby J, Hughes
EG, Collins JA, Sagle MA, YoungLai EV. Natural cycles for in-vitro
fertilization: cost-effectiveness analysis and factors influencing outcome. Hum
Reprod 1995;10(7):1719-24.
-
Dare MR, Crowther CA, Dodd JM, Norman RJ. Single or multiple
embryo transfer following in vitro fertilization for improved neonatal
outcome: A systematic review of the literature. Aust N Z J Obstet Gynaecol
2004;44(4):283-91.
-
Martikainen H, Orava M, Lakkakorpi
J, Tuomivaara L. Day 2 elective single embryo transfer in clinical practice:
better outcome in ICSI cycles. Hum Reprod 2004;19(6):1364-6.
-
Pieper GM, Siebeneich W.
Oral administration of the antioxidant, N-acetylcysteine, abrogates
diabetes-induced endothelial dysfunction. J Cardiovasc Pharmacol
1998;32(1):101-5.
-
Fulghesu AM, Ciampelli M,
Muzj G, Belosi C, Selvaggi L, Ayala GF, et al. N-acetyl-cysteine treatment
improves insulin sensitivity in women with polycystic ovary syndrome. Fertil
Steril 2002;77(6):1128-35.
-
Odetti P, Pesce C,
Traverso N, Menini S, Maineri EP, Cosso L, et al. Comparative trial of
N-acetyl-cysteine, taurine, and oxerutin on skin and kidney damage in long-term
experimental diabetes. Diabetes 2003;52(2):499-505.
-
De Mattia G, Bravi MC,
Laurenti O, Cassone-Faldetta M, Proietti A, De Luca O, et al. Reduction of
oxidative stress by oral N-acetyl-L-cysteine treatment decreases plasma soluble
vascular cell adhesion molecule-1 concentrations in non-obese,
non-dyslipidaemic, normotensive, patients with non-insulin-dependent diabetes.
Diabetologia 1998;41(11):1392-6.
-
Sekhon B, Sekhon C, Khan
M, Patel SJ, Singh I, Singh AK. N-Acetyl cysteine
protects against injury in a rat model of focal cerebral ischemia. Brain
Res 2003;971(1):1-8.
-
Lappas M, Permezel M,
Rice GE. N-Acetyl-cysteine inhibits phospholipid metabolism, proinflammatory
cytokine release, protease activity, and nuclear factor-kappaB deoxyribonucleic
acid-binding activity in human fetal membranes in vitro. J Clin Endocrinol
Metab 2003;88(4):1723-9.
© Copyright 2005 - Middle East Fertility Society
|